Inozyme Pharma, Inc. (INZY) - Net earnings per share (EPS TTM)

Anticipation of the Phase 2 trial results for the treatment of vascular calcification serves as the primary driver for Inozyme Pharma, Inc. (INZY), while current expenditures are already priced in. The development of enzyme-based therapies for rare mineralization pathologies ensures monopoly demand. The lifelong therapy cycle guarantees the business a stable cash flow. Net income per share over 12 months visualizes the capital, where the -1.69 level records the latest values.

INZY (inozyme.com) Earnings per share for the last 12 months history from 07/04/2022 to 07/12/2025

Comprehensive metric breakdowns and analytics for Inozyme (INZY)

- share price and expert price forecast:

Stock Quotes Inozyme Pharma, Inc.|INZY - Forecast Levels Chart

- market capitalization indicators:

Market Capitalization Inozyme Pharma, Inc.|INZY - Total Enterprise Value

- business book valuation details:

Book Value per Share Inozyme Pharma|INZY - Accounting Capitalization|Market Cap to Net Assets Ratio inozyme.com|INZY - Aggregate Asset Value

- debt and liquidity details:

- net income and valuation multiples indicators:

INZY - Net Income|Projected Future Earnings Inozyme Pharma, Inc.|INZY - P/E Multiple|Forward P/E Multiple Inozyme Pharma Inc.|INZY - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma|INZY - Operating profit before amortization|Earnings per share for the last twelve months Inozyme Pharma|INZY - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months inozyme.com|INZY - Earnings per share trend in current year|Expected earnings per share growth for next year Inozyme Pharma, Inc.

- sales volume and revenue information:

INZY - Company Total Revenue|Company Projected Revenue Inozyme Pharma|INZY - Market Cap to Revenue|Forward P/S Multiple Inozyme Pharma, Inc.|INZY - Trailing Twelve Months Revenue Growth

General company analysis:Inozyme Pharma (INZY)

Mass-produced product of Inozyme Pharma Inc.

The market value of Inozyme Pharma, Inc. (INZY) depends directly on capital management efficiency, as reflected by net earnings per share. This metric is calculated by dividing total annual income by the number of securities, which clearly demonstrates the change in TTM net income per share. The stability of this indicator confirms the resilience of the business. For a pharmaceutical company providing lifelong patient treatment, such dynamics guarantee long-term profitability. It is critical for investors to monitor this trend to eliminate the risk of asset overvaluation.

Competitors of Inozyme Pharma, Inc. (INZY)